New Horizons in Anticoagulation: Direct Oral Anticoagulant Use in Special Populations

Thromboembolic disorders such as atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE) remain significant contributors to global morbidity, mortality, and healthcare utilization. The prevalence of atrial fibrillation alone is estimated to exceed 33 million worldwide and continues to grow with population aging and increasing cardiovascular risk factors. Anticoagulation plays a central role in preventing ischemic stroke and recurrent thromboembolism in these patient groups. Historically, vitamin K antagonists (VKAs), such as warfarin, have served as the primary oral anticoagulants. Despite their clinical effectiveness, VKAs carry multiple limitations, including a narrow therapeutic range, variable dose-response relationships, numerous food and drug interactions, and the need for frequent international normalized ratio (INR) monitoring to maintain therapeutic anticoagulation. These challenges contribute to suboptimal adherence, reduced effectiveness, and increased bleeding complications in real-world settings. The introduction of direct oral anticoagulants, including dabigatran, rivaroxaban, apixaban, and edoxaban, has altered the therapeutic landscape by offering targeted inhibition of specific coagulation factors, predictable pharmacokinetics, fewer interactions, and fixed dosing without the need for routine monitoring.^[1][2][3][4] DOACs have demonstrated non-inferiority or superiority to warfarin in prevention of stroke and systemic embolism in AF and in the treatment and secondary prevention of VTE. As a result, DOACs are now widely recommended as first-line oral anticoagulants in multiple international guidelines. Despite these advantages, substantial uncertainty persists regarding DOAC use in patient groups who were excluded or underrepresented in pivotal clinical trials. Large registration trials often limited enrollment based on renal function, liver disease, pregnancy, active malignancy, advanced age, body weight extremes, and concurrent therapies. Consequently, clinicians face challenges in interpreting whether trial outcomes can be extrapolated to high-risk patients commonly encountered in everyday practice. For instance, renal impairment markedly affects the pharmacokinetics of dabigatran and edoxaban due to their high rates of renal elimination, thereby increasing exposure and bleeding risk with standard dosing. ^[5][6] Similarly, hepatic dysfunction alters the metabolism and clearance of factor Xa inhibitors, while cancer patients present dynamic thrombotic and bleeding risks based on tumor biology, chemotherapy regimens, surgical requirements, and thrombocytopenia. Older adults, particularly those over 75 years, may have increased frailty, fall risk, sarcopenia, polypharmacy, and impaired renal function all of which contribute to dosing uncertainty. Additionally, pregnant women and children were excluded from landmark DOAC trials due to safety concerns, leading to continued reliance on LMWH in these groups. Pharmacists, as medication optimization specialists, have become increasingly visible in guiding DOAC therapy selection, dose adjustments, monitoring, counseling, and perioperative planning. Their knowledge of drug properties and patient-specific factors allows them to navigate complexities such as drug–drug interactions, renal function fluctuations, and dose modifications based on evolving clinical status. This review provides a detailed evaluation of current evidence on DOAC pharmacology, clinical outcomes, trial data, real-world registry analyses, and guideline recommendations across special populations. Particular attention is paid to:

• Renal impairment
• Hepatic dysfunction
• Frail elderly
• Cancer-associated thrombosis
• Extremes of body weight
• Pregnancy and lactation
• Pediatric patients
• Perioperative and periprocedural management
• Drug–drug interaction surveillance

Emerging innovations including factor XI inhibitors, pharmacogenomic applications, improved monitoring tools, artificial intelligence-driven risk prediction, and decentralized clinical trials are examined to illustrate future directions for personalized anticoagulation management.

Pharmacology Of DOACS

Direct oral anticoagulants differ from traditional anticoagulants in their molecular targets, pharmacodynamics, and pharmacokinetics. While warfarin inhibits multiple vitamin K–dependent clotting factors (II, VII, IX, X), DOACs exert selective inhibition at a single point in the coagulation cascade. Dabigatran directly inhibits thrombin (factor IIa), while apixaban, rivaroxaban, and edoxaban inhibit activated factor X (factor Xa). These targeted mechanisms enable fast onset of action, predictable-anticoagulation levels, and reduced need for routine coagulation testing. ^[1][2][3][4] The absorption, bioavailability, route of elimination, hepatic metabolism, and half-life differ substantially among DOACs, influencing their safety in organ dysfunction, drug interaction potential, and suitability in complex patient populations. For example, dabigatran is approximately 80% renally cleared, making renal impairment a major determinant of drug accumulation and bleeding risk. In contrast, apixaban has the lowest renal clearance (~27%), offering greater stability and safety in patients with deteriorating kidney function. ^[5][6] Dabigatran undergoes hepatic activation from its prodrug form and is a substrate for P-glycoprotein (P-gp). Rivaroxaban and apixaban undergo varying levels of hepatic metabolism via CYP3A4, meaning co-administration with strong inhibitors or inducers of CYP3A4 or P-gp can significantly affect serum concentrations.^[18][19]  Edoxaban is minimally metabolized by CYP enzymes and is also influenced by renal clearance, although its unique profile includes reduced efficacy at higher creatinine clearance (>95 mL/min), potentially due to insufficient drug exposure at very efficient renal filtration rates.^[4]  These pharmacokinetic variations are essential to clinical decision-making. In patients with severe renal impairment—including dialysis—dabigatran is generally contraindicated, while apixaban may be used with caution and dose reductions based on established criteria. In hepatic impairment, rivaroxaban is unsuitable in moderate to severe dysfunction, while apixaban may be used in mild impairment. In addition, food effects must be considered: rivaroxaban doses of 15–20 mg should be administered with food to ensure adequate absorption, while apixaban and dabigatran absorption are not significantly affected by meals. Beyond individual drug characteristics, DOACs offer advantages over VKAs due to: Rapid onset and offset of action, No routine INR monitoring, Lower rates of intracranial hemorrhage, Predictable dose-response relationships and Fewer dietary restrictions. However, their selectivity and reliance on renal or hepatic pathways also make them more sensitive to organ dysfunction, polypharmacy, and physiologic extremes, particularly among populations excluded from initial trials. Understanding each agent’s pharmacology is therefore a prerequisite to interpreting clinical data in these special settings.

Table 1. Pharmacokinetic Characteristics of Direct Oral Anticoagulants

Clinical Interpretation of Pharmacologic Differences:

Renal Implications

Dabigatran is largely renally cleared, making it high-risk in chronic kidney disease (CKD), with drug accumulation leading to increased bleeding potential. ^[5][6] Apixaban’s lower renal clearance makes it preferable in advanced CKD, including dialysis, where observational studies show lower bleeding compared to warfarin. ^[6] Rivaroxaban and edoxaban require caution but may be used in moderate kidney impairment with dose modifications.

Hepatic Metabolism

Apixaban and rivaroxaban are affected by CYP3A4 and P-gp activity, making them sensitive to strong inhibitors such as ketoconazole or ritonavir, and inducers such as rifampin. In hepatic dysfunction, reduced metabolism may heighten bleeding risk, meaning rivaroxaban should be avoided in Child–Pugh B and C disease, while apixaban may be used cautiously in Child–Pugh B.

Food Interactions

Rivaroxaban requires meal-time dosing at higher strengths, which can influence adherence. The other DOACs are food-independent.

Dosing Frequency and Adherence

Once-daily regimens (rivaroxaban, edoxaban) may improve adherence in some patients; however, twice-daily dosing (apixaban, dabigatran) may offer steadier pharmacodynamic exposure and lower peak–trough variability.

Drug–Drug Interactions

The primary interaction mechanisms involve CYP3A4 and P-gp. Apixaban generally has the fewest clinically significant interaction complications, making it preferred in patients with extensive polypharmacy.

Individualized Selection

Apixaban’s balanced clearance, safety profile, and robust clinical data make it the most versatile DOAC across special populations. Dabigatran may be avoided in patients with renal impairment or gastrointestinal sensitivity due to higher GI bleeding risk. Edoxaban’s unique reduced efficacy in high CrCl (>95 mL/min) is a distinguishing limitation. Rivaroxaban’s reliance on food coadministration and hepatic metabolism make its use more sensitive to adherence and hepatic status.

Role of Reversal Agents

All DOACs now have FDA- or conditionally-approved reversal pathways:

• Dabigatran: Idarucizumab (Praxbind) provides immediate factor IIa reversal.
• Factor Xa inhibitors: Andexanet alfa reverses apixaban and rivaroxaban, though availability and cost may limit use.
• Non-specific reversal options such as four-factor PCC remain valuable in many emergency settings.

These agents provide clinicians and pharmacists with greater confidence in DOAC selection, particularly among high bleeding risk populations.

Pharmacology of DOACs:

Direct oral anticoagulants selectively inhibit specific coagulation pathway targets and differ considerably in absorption, bioavailability, onset, metabolism, elimination, and drug–drug interaction profiles. Understanding these characteristics is critical for choosing the appropriate agent in special populations where physiologic changes may significantly alter drug exposure and safety.

Mechanism of Action

DOACs are divided into two categories:

1. Direct Thrombin Inhibitor (Dabigatran): Inhibits factor IIa (thrombin), preventing conversion of fibrinogen to fibrin and blocking thrombus propagation.
2. Direct Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban): These drugs directly inhibit free and clot-bound factor Xa, reducing thrombin generation and fibrin formation.

Unlike warfarin, DOACs do not affect synthesis of clotting factors, allowing for rapid onset and offset of action.

Absorption and Bioavailability

• Dabigatran is administered as a prodrug requiring acidic gastric environment for absorption. Bioavailability is ~6–7%, making it more susceptible to absorption changes with proton pump inhibitors or gastric surgeries.
• Rivaroxaban has dose-dependent absorption; 15 mg and 20 mg doses require food to achieve adequate bioavailability.
• Apixaban maintains stable absorption independent of food intake.
• Edoxaban demonstrates consistent linear pharmacokinetics.

Protein Binding

High protein binding influences tissue distribution and dialyzability:

• Dabigatran: ~35%
• Rivaroxaban, apixaban, edoxaban: >85%

Consequently, dabigatran is the only DOAC that can be partially removed by dialysis.

Metabolism and Elimination

This variation greatly influences safety and dosing, particularly in Chronic kidney disease, Acute kidney injury, Cirrhosis or hepatic impairment and Drug–drug interaction risk.

Table 2. Key pharmacologic differences among DOACs